Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Unigene Laboratories Inc. Stories

2012-02-07 07:33:00

BOONTON, N.J., Feb. 7, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer will be presenting a corporate overview at the 14th Annual BIO CEO & Investor Conference in New York, NY. Mr. Palmer's presentation is scheduled to begin at 11:00 a.m. ET on Monday, February 13, 2012. Individuals can listen to a...

2012-02-01 08:51:00

BOONTON, N.J., Feb. 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that it has received the 2012 Drug Delivery Partnerships(TM) ("DDP") Innovation Award in the Industry Achievement category in recognition of the Company's 2011 clinical advances in the oral delivery of peptides. This year's DDP Award recipients were voted on and selected by conference attendees, including leading scientists, pharmaceutical executives and drug delivery key...

2012-01-11 07:31:00

BOONTON, N.J., Jan. 11, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office (USPTO). The patent, which was issued on December 13, 2011, provides intellectual property (IP) protection for peptides and pharmaceutical compositions containing such peptides for the suppression...

2012-01-09 07:31:00

BOONTON, N.J., Jan. 9, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a business outlook for 2012 and highlighted multiple near-term catalysts that have the potential to monetize assets and unlock significant value over the next 12 months. Management believes the key elements are in place to address the Company's debt and begin restructuring the balance sheet in 2012. Unigene's CEO, Senior Management and Board of Directors signaled confidence and...

2012-01-04 07:01:00

BOONTON, N.J., Jan. 4, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will present a corporate overview at the Biotech Showcase(TM) 2012 in San Francisco, CA on Monday, January 9, 2012 at 11:30 a.m. PT (2:30 p.m. ET). Mr. Palmer's presentation will include an overview of Unigene's industry-leading oral peptide...

2011-12-19 07:31:00

BOONTON, N.J., Dec. 19, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today highlighted its significant accomplishments in 2011 and announced that its management team has put key elements in place to begin addressing the capital structure and eliminating the inherited debt. Unigene also reaffirmed that the Company's projected cash flow is expected to fund operations into the second half of 2012, following a corporate reorganization to better strategically align...

2011-12-07 07:02:00

BOONTON, N.J., Dec. 7, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will be presenting a corporate overview at the 22nd Annual Oppenheimer Healthcare Conference being held in New York City. Mr. Palmer's live presentation is scheduled to begin at 4:10 p.m. ET on Tuesday, December 13, 2011. A live...

2011-12-05 07:02:00

BOONTON, N.J., Dec. 5, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that the Company terminated its amended and restated exclusive worldwide license agreement and related development services and clinical supply agreement with GlaxoSmithKline (GSK) pertaining to an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women. The termination of these agreements...

2011-11-30 07:02:00

BOONTON, N.J., Nov. 30, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that Cara Therapeutics commenced the Phase 1 study of its oral proprietary peptide-based, investigational drug, CR845, a novel peripherally-acting kappa opioid agonist in healthy volunteers. CR845 oral capsules were formulated using Unigene's validated, proprietary peptide manufacturing...

2011-11-16 06:03:00

BOONTON, N.J., Nov. 16, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the appointment of Thomas J. Sabatino, Jr. to its Board of Directors. Mr. Sabatino is currently Executive Vice President and General Counsel for Walgreen Co., (NYSE: WAG) (NASDAQ: WAG), based in Deerfield, IL. He joined Walgreens in September 2011 after having held general counsel roles with...